InvestingPro’s Fair Value spotted Sana Biotech overvaluation early By Investing.com
InvestingPro's Fair Value analysis accurately predicted the significant overvaluation of Sana Biotechnology (NASDAQ:SANA) in December 2025, when its stock was trading at $5.13. The company's shares subsequently dropped by 43.86%, validating the analysis, which had identified an intrinsic worth of $3.20. While the stock recovered to $3.20 by March 2026, it still remains above its current Fair Value estimate of $2.53, suggesting continued caution for investors despite recent developments like a new CFO and diabetes therapy data.
Sana Biotechnology stock price target lowered to $7 by H.C. Wainwright
H.C. Wainwright has lowered its price target for Sana Biotechnology (NASDAQ:SANA) shares to $7 from $9, while maintaining a Buy rating, citing higher-than-expected operating expenses in Q4 2025. Despite this, the stock has gained over 53% in the past year, and the company reported progress in its cell programs and ended 2025 with $138.4 million in cash. InvestingPro, however, suggests the stock is currently overvalued based on its Fair Value analysis, despite the company's strong current ratio.
SANA PE Ratio & Valuation, Is SANA Overvalued
This article analyzes the valuation of Sana Biotechnology Inc (SANA), concluding that it is currently in the "Fair zone" based on its forward P/S ratio compared to its five-year average. It examines various metrics, including P/B ratio and FCF yield, noting that SANA's P/B ratio is significantly higher than its historical averages while its FCF yield remains negative. The article also compares SANA's P/S ratio to its competitors, highlighting a substantial premium that may be unsustainable given reported revenue growth.
Sana Biotechnology Inc. (SANA) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Sana Biotechnology Inc. (SANA), showing its current stock price and daily performance. It highlights that no analyst ratings or earnings information are currently available for the company. The page also includes promotions for trade alerts and investment tools.
Sana Biotechnology (NASDAQ: SANA) EVP files initial ownership report
Sana Biotechnology's EVP and Chief Scientific Officer, Dhavalkumar Dhirajlal Patel, has filed an initial ownership report (Form 3) detailing his equity interests in the company. The report outlines his stock options, restricted stock units (RSUs), and directly held common stock, all subject to time-based vesting schedules and continuous service conditions. This filing establishes his initial holdings as he becomes subject to SEC insider reporting rules.
Sana Biotechnology (NASDAQ:SANA) Trading Down 7.2% - Here's What Happened
Sana Biotechnology (NASDAQ:SANA) shares dropped 7.2% on Tuesday, trading at about $2.90, after missing its quarterly earnings estimates. The company reported an EPS of ($0.16) against a consensus of ($0.13), and analysts forecast a -1.16 EPS for the current fiscal year. Despite the recent decline, analysts generally have a "Moderate Buy" rating with an average price target of $8.00.
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Recommendation of "Moderate Buy" by Brokerages
Sana Biotechnology (NASDAQ:SANA) has received a consensus "Moderate Buy" recommendation from eight analysts, with an average 1-year price target of $8.00. While some analysts, like Morgan Stanley, maintain a bullish "overweight" rating with a $12 price target, others like Weiss Ratings and Wall Street Zen have issued "sell" ratings. The clinical-stage biopharmaceutical company, with a market cap of $832.63 million, is focused on developing engineered cells as medicines for various diseases.
SANA Forecast, Price Target & Analyst Ratings | SANA BIOTECHNOLOGY INC (NASDAQ:SANA)
This article provides an in-depth analyst forecast for SANA BIOTECHNOLOGY INC (NASDAQ:SANA), detailing an average price target of $8.33, representing a potential 185.28% upside. It includes various analyst ratings, historical data, upcoming earnings estimates for Q1 2026, and long-term growth forecasts for EPS, revenue, EBIT, and EBITDA. The consensus rating from 15 analysts is strongly optimistic, with 85.33% recommending a 'Buy.'
Sana Biotechnology (SANA) appoints industry veteran Brian Piper as new CFO
Sana Biotechnology (SANA) has announced the appointment of industry veteran Brian Piper as its new Chief Financial Officer. Piper brings extensive experience in the biotechnology and pharmaceutical sectors, which is expected to support Sana Biotechnology's financial strategies and growth. This strategic hire aims to strengthen the company's executive leadership as it continues to advance its therapeutic programs.
Sana’s Cell Therapy Sustains Insulin Production Through 14 Months in a T1D Patient
Sana Biotechnology's investigational allogeneic islet cell therapy, UP421, has shown sustained insulin production for over 14 months in a Type 1 Diabetes patient without immunosuppression. This therapy, which utilizes Sana's hypoimmune platform, evaded the immune system and maintained pancreatic islet cell function. Building on these positive results, Sana plans to advance its preclinical candidate SC451, which employs a similar approach, into Phase 1 studies this year, aiming to provide a durable treatment for T1D patients without the need for exogenous insulin or immunosuppression.
Sana’s islet cell transplant therapy shows early promise in type 1 diabetes
Sana Biotechnology's hypoimmune (HIP)-modified islet cell therapy showed promising results in a first-in-human study for type 1 diabetes. Long-term data demonstrated sustained survival and function of pancreatic beta cells without immunosuppression, leading to improved glycemic control and insulin secretion. This therapy offers a potential functional cure for type 1 diabetes, building on recent advancements in the field.
Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana Biotechnology announced positive 14-month clinical results from a first-in-human study of UP421, a hypoimmune-modified islet cell therapy, for Type 1 Diabetes without immunosuppression. The study showed sustained survival and function of transplanted cells, consistent insulin production, and no safety issues. These findings support Sana's hypoimmune platform and its potential for a more scalable stem cell-derived therapy, SC451, aiming for normal blood glucose without insulin or immunosuppression, with an IND application expected this year.
Morgan Stanley reiterates Sana Biotechnology stock rating on diabetes data
Morgan Stanley has maintained an Overweight rating and a $12.00 price target for Sana Biotechnology (NASDAQ:SANA) following positive clinical data updates regarding its UP421 program for type 1 diabetes. Despite a 24% year-to-date stock decline, the firm sees the durability of immune evasion as a significant de-risking event. The next catalyst is expected to be the SC451 IND and Phase 1 initiation later this year, though the company faces challenges with quickly burning through cash.
Integral Health Asset Management LLC Has $7.10 Million Stock Position in Sana Biotechnology, Inc. $SANA
Integral Health Asset Management LLC increased its holding in Sana Biotechnology, Inc. (NASDAQ:SANA) by 33.3%, now owning 2 million shares valued at $7.1 million. Other institutional investors like Baillie Gifford, Vanguard, JPMorgan, and UBS also increased their stakes, bringing total institutional ownership to 88.23%. Despite missing recent earnings estimates, analysts maintain a "Moderate Buy" rating with a consensus price target of $8.00.
Sana Biotechnology (NASDAQ:SANA) Trading Up 7.8% - Here's What Happened
Sana Biotechnology (NASDAQ:SANA) shares rose 7.8% to $3.33 mid-day on Friday, March 13, 2026, despite a 60% decline in trading volume. The company, which is focused on developing engineered cells as medicines, has an average analyst rating of "Moderate Buy" with a $7.83 price target, though recent analyst actions have been mixed. Institutional investors hold a significant portion of the shares, with several large funds increasing their positions, even as the company missed recent earnings estimates.
Morgan Stanley Maintains Overweight on Sana Biotechnology, Inc. (SANA) March 2026
Morgan Stanley reiterated an Overweight rating on Sana Biotechnology, Inc. (SANA) on March 13, 2026, following a company update that the firm described as a "meaningful platform level de-risking event." This reiteration, which did not include a new price target, led to a modest 1.82% intraday stock movement, indicating the market viewed it as positive but not transformative. Meyka AI also rates SANA with a B grade, advising investors to combine this analyst rating with other catalysts for informed decision-making.
Sana Biotechnology Gains on Positive Results for Type 1 Diabetes Study
Sana Biotechnology (SANA) stock increased by 8.74% after positive results were announced for its Type 1 Diabetes study. The article also mentions Unity Software's (U.US) fourth-quarter financial results, reporting revenue of $609 million and a quarterly loss of 66 cents per share.
Transplanted insulin cells work 14 months without immune drugs in T1D patient
Sana Biotechnology reported positive 14-month follow-up results from a first-in-human study of HIP-modified primary islet cells (UP421) transplanted into a Type 1 Diabetes patient without immunosuppression. The cells demonstrated sustained survival and function, with C-peptide levels comparable to the first six months and no safety issues identified. Sana plans to file an IND for its SC451 program and initiate a Phase 1 trial as early as this year, aiming for a scalable, one-time treatment for Type 1 Diabetes without insulin or immunosuppression.
Sana sees 14-month insulin production for transplanted islet therapy in single Type 1 diabetes patient
Sana Biotechnology shared 14-month follow-up data for its investigational allogeneic cell therapy, UP421, showing continued insulin production and no safety concerns in a single Type 1 diabetes patient. The therapy, transplanted into the patient's arm, avoided immune rejection and maintained C-peptide levels comparable to early study results. Sana plans to submit an IND application for a more scalable stem cell-derived therapy, SC451, hoping to launch a Phase 1 trial this year.
SANA: Hypoimmune and in vivo CAR T platforms advance toward clinical trials, with key data expected soon
Sana Biotechnology (SANA) is making progress with its hypoimmune cell therapies for Type 1 diabetes, highlighted by a successful year-long human case and manufacturing advancements. The company's in vivo CAR T cell programs are slated for clinical trials this year, with initial human data anticipated by the end of 2026. This information was presented at the Citizens Life Sciences Conference 2026.
Sana (SANA) CEO Steve Harr vests RSUs and uses 24,345 shares for tax
Sana Biotechnology (SANA) CEO Steve Harr recently vested restricted stock units (RSUs), acquiring 91,666 common shares at a $0.00 exercise price. To cover tax liabilities associated with these vestings, Harr disposed of 24,345 shares at prices around $3.10 to $3.13 per share. Following these routine compensation transactions, Steve Harr directly holds 7,944,251 shares of SANA common stock, in addition to indirect holdings through family trusts.
Sana Diabetes Data And Funding Moves Reframe Risk For NasdaqGS SANA Investors
Sana Biotechnology reported positive 12-month results from its UP421 type 1 diabetes trial and announced plans for further clinical development in diabetes and cancer. The company also appointed a new CFO and enhanced its capital raising flexibility. While the clinical data strengthens its outlook, investors face risks due to the company's ongoing losses, lack of revenue, and short cash runway, making future funding crucial.
Sana Biotechnology (SANA) Expected to Announce Quarterly Earnings on Monday
Sana Biotechnology (SANA) is expected to announce its Q4 2025 earnings before market open on Monday, March 16th, with analysts forecasting a loss of ($0.12) per share. The company previously missed Q3 2025 estimates, reporting ($0.16) EPS against a consensus of ($0.13). Institutional ownership is high, but analyst sentiment is mixed, marked by recent downgrades and concerns over execution and cash runway.
Sana Diabetes Data And Funding Moves Reframe Risk For NasdaqGS SANA Investors
Sana Biotechnology (NasdaqGS:SANA) released positive 12-month results from its UP421 type 1 diabetes trial, showing promising functionality of hypoimmune pancreatic islet cells. The company also announced plans for new cell therapy candidates, a new CFO, and expanded capital raising flexibility. While these updates provide new clinical milestones, investors are cautioned about the company's less than one year of cash runway, unprofitability, and recent shareholder dilution, making financing risk a central factor.
Sana Diabetes Data And Funding Moves Reframe Risk For NasdaqGS SANA Investors
Sana Biotechnology reported positive 12-month results from its UP421 type 1 diabetes trial and announced plans for further clinical development in diabetes and cancer. The company also appointed a new CFO and amended its equity sales agreement to enhance capital-raising flexibility. Despite a multiyear decline, these developments and financing adjustments could reframe investor sentiment for Sana Biotechnology.
Year-long diabetes cell transplant works without immune drugs in Sana study
Sana Biotechnology reported its Q4 and full-year 2025 financial results, highlighting major clinical advancements in its hypoimmune platform for type 1 diabetes and its fusogen platform for in vivo CAR T therapies. The company announced successful one-year results for its UP421 hypoimmune islet cell transplant, showing function without immunosuppression, and plans to advance its SC451 and SG293 candidates into clinical trials in 2026. Despite a net loss, Sana ended 2025 with $138.4 million in cash, projecting a runway into late 2026 due to reduced R&D spending and strategic financing.
Q1 EPS Estimate for Sana Biotechnology Lowered by Analyst
HC Wainwright has lowered its Q1 2026 EPS estimate for Sana Biotechnology (NASDAQ: SANA) to ($0.14) from ($0.08), while maintaining a "Buy" rating and a $7.00 price target. The company recently reported ($0.16) EPS for the last quarter, missing the consensus of ($0.13), and the full-year EPS consensus is now ($1.16). Despite the lowered estimates, Sana Biotechnology has a consensus "Moderate Buy" rating from analysts with a target price of $7.83, significantly higher than its current share price of $3.41.
Citizens reiterates Sana Biotechnology stock rating on pipeline progress
Citizens has reiterated a Market Outperform rating and an $8.00 price target for Sana Biotechnology (NASDAQ:SANA) shares, citing the company's current cash position and pipeline progress. Despite some overvaluation concerns from InvestingPro, the firm maintains that Sana shares are undervalued, with its lead programs SC451 and SG293 on track for clinical trials and first-in-human readouts as early as 2026. The company recently reported its Q4 2025 financial results, including a cash position of $138.4 million, and announced the appointment of Brian Piper as EVP and CFO.
Sana Biotechnology (SANA) Q4 2025 Financial Results: Net Loss and Analyst Outlook - News and Statistics
Sana Biotechnology Inc. (SANA) reported a Q4 2025 net loss of $58.8 million, or 21 cents per share, which was worse than Wall Street's expectation of a 13 cents per share loss. For the entire year 2025, the company posted a loss of $244.2 million, or 96 cents per share. This financial update also highlights various market research chapters offered by IndexBox.
AI Adoption Exposes Sana Biotechnology to Rising Data, Compliance, and Reputational Risks
Sana Biotechnology, Inc. (SANA) faces significant risks due to its reliance on rapidly evolving AI and GenAI tools, which could lead to strategic lag or operational disruption if not effectively managed. The adoption of AI also exposes the company to data leakage, IP contamination, and privacy liabilities, alongside increased compliance costs and reputational harm from emerging global AI regulations. Despite these risks, Wall Street analysts currently hold a Moderate Buy consensus rating for SANA stock.
Sana Biotechnology stock price target lowered to $7 by H.C. Wainwright
H.C. Wainwright has reduced its price target for Sana Biotechnology (NASDAQ:SANA) shares to $7 from $9, while maintaining a Buy rating, citing higher-than-expected operating expenses in Q4 2025. Despite recent volatility, the stock has gained over 53% in the past year. Sana Biotechnology announced progress in its cell therapy programs, including updated positive 12-month durability results for its UP421 trial, and appointed Brian Piper as its new Executive Vice President and CFO.
Sana Biotechnology Diabetes Data And CAR T Plans Shape Pipeline Outlook
Sana Biotechnology (NasdaqGS:SANA) reported positive 12-month clinical data from its type 1 diabetes study, showing safety, tolerability, and continued function of its hypoimmune modified pancreatic islet cell therapy without chronic immunosuppression. The company plans to file an IND for its SC451 therapy and expects first-in-human data this year from a new in vivo CAR T program. These developments position Sana Biotechnology with promising clinical milestones in both diabetes and oncology, while investors will monitor upcoming regulatory filings, trial readouts, and capital-raising activities.
Sana Biotechnology (NASDAQ:SANA) Price Target Lowered to $7.00 at HC Wainwright
HC Wainwright lowered its price target for Sana Biotechnology (NASDAQ:SANA) from $9.00 to $7.00, while maintaining a "buy" rating, indicating a potential 78% upside. The company reported a quarterly EPS miss of ($0.16) against a consensus of ($0.13), and analysts anticipate an EPS of -1.16 for the current fiscal year. Despite the target cut, Sana Biotechnology holds a consensus "Moderate Buy" rating with an average target price of $7.83 from various analysts.
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Sana Biotechnology reported its fourth quarter and full year 2025 financial results, highlighting significant progress in its hypoimmune and fusogen platforms. The company shared positive 12-month clinical results for its UP421 type 1 diabetes study and intends to file an IND for SC451, a next-generation therapy for type 1 diabetes, as well as generate first-in-human data for SG293 in blood cancers this year. Financially, Sana ended 2025 with $138.4 million in cash and expects its cash runway to extend into late 2026, after raising $133.7 million in gross proceeds in 2025.
Sana Biotechnology Files For Mixed Shelf Size Not Disclosed - SEC Filing
Sana Biotechnology (SANA) has filed for a mixed shelf offering, according to an SEC filing. The size of the offering was not disclosed. This news was originally reported by Reuters and republished by TradingView.
Sana: Overview of Fourth Quarter Financial Results
Sana Biotechnology Inc. reported a net loss of $58.8 million for the fourth quarter, or $0.21 per share. When excluding one-time expenses, the adjusted loss was $0.16 per share, which did not meet analysts' consensus estimates of a $0.13 per share loss.
Sana Biotechnology (NASDAQ: SANA) sets $150.0 million ATM program
Sana Biotechnology has established a new $150.0 million "at-the-market" (ATM) stock program through an amended sales agreement with TD Cowen. This program provides the company with flexible capital access following a year in which it raised $133.7 million from equity, while also reporting a significant reduction in GAAP net loss for 2025 and projecting its cash runway into late 2026. The company also announced encouraging clinical progress in its type 1 diabetes and CAR T cell therapy programs.
Sana Biotechnology files for mixed shelf size not disclosed - SEC filing
Sana Biotechnology, Inc. has filed for a mixed shelf offering, the size of which has not been disclosed, according to a recent SEC filing. This news was published on March 3, 2026, and follows other recent company updates including presentations at healthcare conferences and quarterly earnings reports. The company is focused on developing engineered cells as medicines for various therapeutic areas.
SANA SEC Filings - Sana Biotechnology, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Sana Biotechnology, Inc. (SANA) SEC filings, including 10-K, 10-Q, and 8-K reports. It details recent material events such as a board member's resignation, asset write-downs, financial results, and capital raises through public offerings. The platform also offers AI-powered summaries to help investors understand the significance of each regulatory document and tracks clinical trial progress for programs like UP421.
Sana Biotechnology, Inc. (SANA): A Bull Case Theory
This article summarizes a bullish thesis on Sana Biotechnology, Inc. (SANA), highlighting its gene-edited, hypoimmune cell therapy, SC451, for type 1 diabetes. The company's technology is presented as a significant advancement over competitors due to its "invisibility" to the immune system and potential for scalable production. Key catalysts include an upcoming Investigational New Drug (IND) filing and progression of stem-cell trials, which could transform SANA into a major biotech platform.
Will Sana’s New Veteran Biopharma CFO Appointment Change Sana Biotechnology's (SANA) Investment Narrative
Sana Biotechnology recently appointed Brian Piper as its new CFO, bringing extensive biopharma finance and IPO experience to the company. While this move may improve financial management and investor communication, it does not alleviate the core investment risks, such as heavy losses, zero revenue, and ongoing dilution. The article suggests that Sana's share price might be inflated compared to its estimated value, urging investors to consider various viewpoints and conduct thorough research.
Sana Biotechnology, Inc. (SANA): A Bull Case Theory
This article summarizes a bull thesis on Sana Biotechnology, Inc. (SANA) from Stock Invader's Substack, highlighting its lead in type 1 diabetes treatment with hypoimmune cell therapy SC451. SANA's technology, which enables insulin independence without immunosuppression, is seen as superior to competitors, with significant scalability potential. Key catalysts include the upcoming IND filing and stem-cell trial progress, which could attract acquisition interest and offer substantial investor returns despite high risk.
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Recommendation of "Moderate Buy" by Analysts
Sana Biotechnology, Inc. (NASDAQ:SANA) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $8.17. Institutional ownership is high at 88.23%, with several major firms recently increasing their stakes. The company's shares opened at $4.27, have a market cap of $1.14 billion, and are trading near their 50- and 200-day moving averages.
Will Sana’s New Veteran Biopharma CFO Appointment Change Sana Biotechnology's (SANA) Investment Narrative
Sana Biotechnology recently appointed Brian Piper, M.B.A., as its new CFO, bringing extensive biopharma finance experience to the company. This appointment could influence Sana's approach to capital allocation and investor relations, especially given its current financial challenges including heavy losses, no revenue, and shareholder dilution. While the CFO change does not eliminate core risks, Piper's expertise may help manage the company's cash runway and future funding strategies.
Sana Biotechnology (SANA) Appoints Industry Veteran Brian Piper as New CFO
Sana Biotechnology Inc. (NASDAQ: SANA) has appointed Brian Piper as its new Executive Vice President and Chief Financial Officer. Piper brings over 25 years of biopharmaceutical experience and will be crucial as the company approaches major clinical milestones, including data readouts for its SC451 and SG293 therapies. His role will focus on capital allocation and maintaining a strong financial position to support the development of Sana's cell therapy portfolios.
Will Sana’s New Veteran Biopharma CFO Appointment Change Sana Biotechnology's (SANA) Investment Narrative
Sana Biotechnology recently appointed Brian Piper as CFO, a move that could reshape the company's financial approach and investor engagement. While his experience may influence spending and funding strategies, the core investment case still hinges on whether its cell and gene therapy platforms can justify ongoing losses and lack of revenue. The company faces concerns about its cash runway and a potentially inflated share price, with a wide range of fair value estimates from the Simply Wall St community.
SANA Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Sana Biotechnology, Inc. (SANA), including its income statement, balance sheet, cash flow statement, and key financial ratios. It highlights that SANA reported a net income loss of -$266.8M in fiscal year 2024 and had an estimated cash runway of only 7 months based on its operating cash burn. The company also demonstrates weak financial health with a Piotroski F-Score of 2/9 and low earnings quality, suggesting profits are more accrual-driven than cash-generated.
Assessing Sana Biotechnology (SANA) Valuation After Recent Share Price Momentum
Sana Biotechnology (SANA) has experienced recent share price momentum, exhibiting a 5.71% gain over the past week and a 41.32% one-year total shareholder return, contrasting with a significant five-year loss. Despite trading at a Price-to-Book ratio of 5.6x, indicating a richer valuation than the broader US biotech group, this is lower than a select peer group. The article highlights that while the stock appears valued for its pipeline, investors must consider ongoing net losses and reliance on clinical milestones.
Assessing Sana Biotechnology (SANA) Valuation After Recent Share Price Momentum
Sana Biotechnology (SANA) has experienced mixed share performance recently, with a short-term gain contrasting with a longer-term decline. The article assesses the company's valuation, noting its Price-to-Book ratio of 5.6x, considered "about right" despite being higher than the broader US biotech group but lower than a concentrated peer set. The valuation takes into account Sana's early-stage focus, reliance on clinical milestones, and ongoing net losses.
Sana Biotechnology to Present at March 2026 Investor Conferences
Sana Biotechnology, Inc. announced it will webcast presentations at two investor conferences in March 2026: the Cowen 46th Annual Health Care Conference on March 2nd and the Citizens Life Sciences Conference on March 11th. The presentations will provide a business overview and updates, with webcasts available on Sana's Investor Relations page. The company focuses on developing engineered cells as medicines.
